Xenon PharmaceuticalsXENE
About: Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Employees: 327
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
5,216% more call options, than puts
Call options by funds: $4.36M | Put options by funds: $82K
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
44% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 13 (+4) [Q4]
3% more funds holding
Funds holding: 201 [Q3] → 208 (+7) [Q4]
1.24% more ownership
Funds ownership: 98.82% [Q3] → 100.06% (+1.24%) [Q4]
1% more capital invested
Capital invested by funds: $2.95B [Q3] → $2.99B (+$41.4M) [Q4]
6% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 69
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Goldman Sachs Paul Choi 53% 1-year accuracy 8 / 15 met price target | 50%upside $52 | Buy Maintained | 17 Apr 2025 |
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 30 / 172 met price target | 53%upside $53 | Buy Reiterated | 24 Feb 2025 |
Deutsche Bank David Hoang 12% 1-year accuracy 2 / 17 met price target | 93%upside $67 | Buy Initiated | 11 Feb 2025 |
Financial journalist opinion
Based on 4 articles about XENE published over the past 30 days









